Characterization of Biotherapeutics with High-Resolution Ion Mobility-Mass Spectrometry
Posters | 2022 | MOBILion Systems | ASMSInstrumentation
Comprehensive characterization of biotherapeutics is crucial to guarantee their safety, efficacy, and consistency in manufacturing and clinical applications. Traditional analytical approaches rely on separate liquid chromatography–mass spectrometry (LC-MS) methods for intact proteins, subunit analysis, peptide mapping, and released glycan profiling. Incorporating high-resolution ion mobility into LC-MS workflows provides an additional separation dimension that enhances the resolution of isoforms, post-translational modifications, and glycan isomers, thereby streamlining quality control and accelerating biopharmaceutical development.
This work demonstrates a unified platform combining liquid chromatography–high-resolution ion mobility–mass spectrometry (LC-HRIM-MS) with Protein Metrics Byos software for HRIM data processing. The goal is to consolidate four key workflows—intact protein analysis, subunit separation, peptide mapping, and released glycan profiling—into a single instrument setup. The study evaluates the performance, reproducibility, and quantitative capabilities of this integrated approach for monoclonal antibody characterization.
Sample Preparation and Workflows:
Intact and Subunit Analysis:
The combined LC-HRIM-MS platform with Protein Metrics Byos HRIM workflows delivers a robust, single-instrument solution for in-depth biotherapeutic characterization. By adding high-resolution ion mobility to conventional LC-MS methods, this approach enhances separation of subunits, peptides, and glycans, increases confidence in PTM detection, and streamlines data analysis. The unified workflow can support diverse applications in biologics development, quality control, and biosimilarity assessment.
No external references were provided in the source document.
Ion Mobility, LC/TOF, LC/HRMS, LC/MS, LC/MS/MS
IndustriesPharma & Biopharma
ManufacturerAgilent Technologies, MOBILion Systems
Summary
Significance of the Topic
Comprehensive characterization of biotherapeutics is crucial to guarantee their safety, efficacy, and consistency in manufacturing and clinical applications. Traditional analytical approaches rely on separate liquid chromatography–mass spectrometry (LC-MS) methods for intact proteins, subunit analysis, peptide mapping, and released glycan profiling. Incorporating high-resolution ion mobility into LC-MS workflows provides an additional separation dimension that enhances the resolution of isoforms, post-translational modifications, and glycan isomers, thereby streamlining quality control and accelerating biopharmaceutical development.
Aims and Overview of the Study
This work demonstrates a unified platform combining liquid chromatography–high-resolution ion mobility–mass spectrometry (LC-HRIM-MS) with Protein Metrics Byos software for HRIM data processing. The goal is to consolidate four key workflows—intact protein analysis, subunit separation, peptide mapping, and released glycan profiling—into a single instrument setup. The study evaluates the performance, reproducibility, and quantitative capabilities of this integrated approach for monoclonal antibody characterization.
Methodology and Instrumentation
Sample Preparation and Workflows:
- Intact Protein: Analysis of a humanized monoclonal antibody standard without prior digestion.
- Subunit Analysis: Reduction of the mAb into light chain (LC) and heavy chain (HC) subunits.
- Peptide Mapping: Denaturation with guanidine HCl, reduction with DTT, alkylation with IAA, tryptic digestion, and desalting for peptide-level PTM identification.
- Released Glycan Analysis: Enzymatic release of N-glycans, labeling with Rapifluor MS reagent, and HILIC separation.
- Liquid Chromatography: Agilent 1290 Infinity II UHPLC.
- Columns: PLRP-S for intact/subunit, Waters BEH C18 for peptides, Zorbax HILIC Plus for glycans.
- Mass Spectrometry: Agilent 6545XT Q-TOF system equipped with MOBIE™ HRIM for high-resolution ion mobility separation.
- Data Acquisition and Processing: EyeOn and MassHunter software for acquisition, IM-MS Browser for visualization, Protein Metrics Byos for HRIM workflows including intact, subunit, peptide, and glycan modules.
Main Results and Discussion
Intact and Subunit Analysis:
- The HRIM dimension enabled clear separation of LC and HC subunits, improving deconvolution accuracy and mass precision (mass errors <5 ppm).
- Mobility separation distinguished modified versus unmodified peptides, enhancing confidence in identifying deamidation, isomerization, oxidation, and glycation sites with reproducible percent modifications across replicates.
- Glycopeptide isomers were resolved in the mobility domain, allowing relative quantitation of site-specific glycosylation variants.
- Distinct mobility features separated released glycan isomers and enabled accurate relative abundance measurements over six replicates with high reproducibility.
Benefits and Practical Applications
- Single-platform approach reduces instrument turnover and method development time for multi-level characterization.
- High-resolution ion mobility adds an orthogonal separation that resolves coeluting species and improves specificity for complex PTMs and glycoforms.
- Streamlined data processing with Protein Metrics Byos accelerates reporting and decision-making in development, QC, and biosimilar comparability studies.
Future Trends and Opportunities
- Integration of ion mobility with emerging fragmentation techniques and higher-field instruments to further enhance structural elucidation.
- Application of the unified LC-HRIM-MS platform to newer biotherapeutic modalities (e.g., antibody-drug conjugates, bispecific antibodies, novel fusion proteins).
- Implementation of machine learning algorithms for automated feature annotation, PTM localization, and isomer classification.
- Expansion into regulated QC workflows, supporting real-time process monitoring and in-line analytics.
Conclusion
The combined LC-HRIM-MS platform with Protein Metrics Byos HRIM workflows delivers a robust, single-instrument solution for in-depth biotherapeutic characterization. By adding high-resolution ion mobility to conventional LC-MS methods, this approach enhances separation of subunits, peptides, and glycans, increases confidence in PTM detection, and streamlines data analysis. The unified workflow can support diverse applications in biologics development, quality control, and biosimilarity assessment.
References
No external references were provided in the source document.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Protein solutions eBook
2024|Thermo Fisher Scientific|Guides
Biopharma Protein solutions eBook Protein therapeutics: At a glance Protein therapeutics are a type of biotherapeutics derived from genetically engineered human proteins. They offer several advantages over small-molecule drugs, allowing for more precise targeting of complex functions. Compared to chemical…
Key words
thermo, thermoscientific, scientificprotein, proteinvanquish, vanquishorbitrap, orbitrapanalysis, analysisintact, intactuhplc, uhplcduo, duobiopharma, biopharmacharacterization, characterizationpeptide, peptideattribute, attributemapping, mappingsubunit
Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q‑TOF
2018|Agilent Technologies|Applications
Application Note Biotherapeutics and Biosimilars Profiling Glycosylation of Monoclonal Antibodies at Three Levels Using the Agilent 6545XT AdvanceBio LC/Q‑TOF Author Introduction David L. Wong Agilent Technologies, Inc. Santa Clara, CA, USA Monoclonal antibodies (mAbs) and their derivatives represent a very…
Key words
glycan, glycanglycoforms, glycoformsmab, mabnistmab, nistmabquantitation, quantitationintact, intactagilent, agilentglycans, glycansassaymap, assaymapadvancebio, advancebiomapping, mappingbioconfirm, bioconfirmbravo, bravocounts, countsdeconvoluted
Peptide Mapping on Monoclonal Antibodies Using Agilent 6545XT AdvanceBio LC/Q-TOF and Protein Metrics Byos Software
2021|Agilent Technologies|Applications
Application Note Biotherapeutics and Biosimilars Peptide Mapping on Monoclonal Antibodies Using Agilent 6545XT AdvanceBio LC/Q-TOF and Protein Metrics Byos Software Author Linfeng Wu Agilent Technologies, Inc. Santa Clara, CA, USA Introduction Liquid chromatography/mass spectrometry (LC/MS) plays an increasingly critical role…
Key words
byos, byospeptide, peptidedeamidated, deamidatednistmab, nistmabprotein, proteinmapping, mappingagilent, agilentwildtype, wildtypeassaymap, assaymapptm, ptmbravo, bravodata, datacharacterization, characterizationmam, mamtof
BIOPHARMACEUTICAL - Key Applications
2016|Waters|Guides
BIOPHARMACEUTICAL PLATFORM SOLUTION Key Applications TABLE OF CONTENTS Biopharmaceutical Platform Solution with UNIFI: Key Applications Intact Protein MS Analysis I Peptide Mapping I Released Glycan Analysis I Bioseparations Biotherapeutic proteins – such as monoclonal antibodies (mAbs), biosimilars, and antibody drug…
Key words
unifi, unifibiopharmaceutical, biopharmaceuticaluplc, uplcglycan, glycanacquity, acquityglycoworks, glycoworksplatform, platformglycans, glycanspeptide, peptideanalysis, analysisbiosimilar, biosimilarsolution, solutionintact, intactwaters, watersinnovator